NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Provides Summary of 2010 Accomplishments and 2011 Outlook

EMERYVILLE, Calif., Feb. 2, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of antibiotic-resistant infections, provided a synopsis of its accomplishments and progress during 2010, as well as the company’s outlook for 2011.